ABOUT US

History

HEM Pharma has been constantly making efforts to add more abundance and happiness to life of human beings. In order to change the world with new challenges to realize the ideal life that everyone dreams of, HEM Pharma will continue to open a new history in the microbiome field through technological innovation that goes beyond limits.

2022
October
HEM1036 Phase 2 HREC approval (AU)
September
Obtained A grade in ‘Innobiz’, a technology innovation certification system
(Ministry of SMEs and Startups, MSS)
June
Selected as a preliminary unicorn company
Ministry of SMEs and Startups, MSS)
May
3rd party allotment paid-in capital increase \10.9b (cumulative \48.7b)
February
Establishing U.S. intestinal microbiome data through
clinical research agreement with Endominance
2021
December
Receiving the grand prize at '2021 Korea's Excellent Patent'
May
Changing company name to HEM Pharma Inc
February
GMP production facility completed
January
Launching Amway Balace Within Immunity
2020
September
Starting LARS efficacy evaluation clinical start,
ISO 9001 quality management system certification
April
Changing company name to HEM Inc,
Launching post-synergy service
March
Launching intestinal microbe-metabolome research service
January
Contracting an exclusive contract for the sale of Access
Business Group My Lab Service
2019
September
Concluding a business contract with COSMAX NBT for research
exchange and cooperation in product development and sales
2018
December
Certification of Korea Venture Company
June
Recognition as a corporation affiliation research institute
April
Establishing HEM Suwon Gwanggyo branch of Advanced Institute of
Convergence Technology
2017
August
Concluding MOU with Lactomason Inc. and proceeding technology transfer
From May
to present
Israel’s Better Air won a contract to transfer useful microbial technology
for a total of $600,000 worth of environmental purification
January
Starting the business of Holzapfel Effective Microbes
(2016.12.30 establishment registration)